SCHEMBL9751764

SCHEMBL9751764

CCOC(=O)C(=O)OCC.[NaH]

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.59
LMNA P02545 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ALOX15 P16050 1/20 0.53
MGAM O43451 1/20 0.53
GAA P10253 1/20 0.53
SI P14410 1/20 0.53
MGAM2 Q2M2H8 1/20 0.53
SOAT1 P35610 1/20 0.53
NPSR1 Q6W5P4 1/20 0.52
GLO1 Q04760 1/20 0.52
TSHR P16473 2/20 0.50
EGLN1 Q9GZT9 1/20 0.48
TRPA1 O75762 1/20 0.48
MAPT P10636 2/20 0.46
CYP2D6 P10635 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HCAR2 Q8TDS4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28251428 1.00 ALDH1A1 (0.59) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL7262 0.96 ALDH1A1 (0.62) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL9823358 0.96 ALDH1A1 (0.62) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL1331989 0.96 ALDH1A1 (0.62) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL30076441 0.93 ALDH1A1 (0.59) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL11597524 0.93 ALDH1A1 (0.59) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL28824460 0.93 ALDH1A1 (0.59) ALDH1A1LMNAHSD17B10ALOX15MGAM
Ammonia Solution, Strong SCHEMBL12803984 0.93 ALDH1A1 (0.59) ALDH1A1LMNAHSD17B10ALOX15MGAM
Methyl Alcohol SCHEMBL28343801 0.93 ALDH1A1 (0.59) ALDH1A1LMNAHSD17B10ALOX15MGAM
SCHEMBL11597527 0.93 ALDH1A1 (0.59) ALDH1A1LMNAHSD17B10ALOX15MGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0435952-A4 PREPARATION OF SODIUM DIETHYL OXALACETATE 1991-08-21 EP claimed
EP-0435952-A1 PREPARATION OF SODIUM DIETHYL OXALACETATE HOECHST CELANESE CORPORATION (US) 1991-07-10 EP claimed
WO-1990003361-A1 PREPARATION OF SODIUM DIETHYL OXALACETATE HOECHST CELANESE CORPORATION (US) 1990-04-05 WO claimed
US-4902819-A Preparation of sodium diethyl oxalacetate HOECHST CELANESE CORPORATION (US) 1990-02-20 US claimed
CN-118302411-A Therapeutic indazole compounds and methods of use thereof for the treatment of cancer 基因泰克公司 2024-07-05 CN disclosed
CN-115867557-A Azepine fused ring compounds and medical application thereof 中国医药研究开发中心有限公司 2023-03-28 CN disclosed
CN-114805065-A Preparation method of oxalyl chloride monoester 阜新孚隆宝医药科技有限公司 2022-07-29 CN disclosed
EP-2847191-B1 SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS SANOFI SA (FR) 2016-06-15 EP disclosed
EP-2760862-B1 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS SANOFI SA (FR) 2015-10-21 EP disclosed
US-9133181-B2 Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors SANOFI (FR) 2015-09-15 US disclosed
US-20150133432-A1 SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS SANOFI (FR) 2015-05-14 US disclosed
EP-2847191-A1 SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS SANOFI (FR) 2015-03-18 EP disclosed
EP-2760862-A1 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS SANOFI (FR) 2014-08-06 EP disclosed
WO-2013167403-A1 SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS SANOFI (FR) 2013-11-14 WO disclosed
US-20130085128-A1 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors SANOFI (FR) 2013-04-04 US disclosed
WO-2013045413-A1 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS SANOFI (FR) 2013-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133432-A1 SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS MAP3K1, MAP3K6, MAP3K19 ALDH1A1 1514/4885LMNA 3821/4885HSD17B10 3063/4885
US-20130085128-A1 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors MAP3K1, MAP3K6, MAP4K2 ALDH1A1 1088/4885LMNA 3735/4885HSD17B10 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.